GlassScriptPhysician profile
Lawrence D Shulman
NPI 1265471585
$227,893.26
in general payments reported to CMS, 2019-2025
37 companies · $26K in 2025
The $26K reported for 2025 was more than what 96% of Pulmonary Disease providers received nationally (typical 2025 total: $500).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $4,711 · 2020: $16K · 2021: $36K · 2022: $31K · 2023: $71K · 2024: $43K · 2025: $26K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $126K · Travel and Lodging: $7,274 · Food and Beverage: $5,486 · Consulting Fee: $1,400 · Education: $137.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $125,700.00 |
| Travel and Lodging | $7,273.93 |
| Food and Beverage | $5,486.30 |
| Consulting Fee | $1,400.00 |
| Education | $136.99 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Glaxosmithkline, LLC. | $212,424.94 | 2019-2025 | Arexvy, Trelegy Ellipta, Nucala |
| Pfizer INC. | $6,794.06 | 2019-2025 | |
| Viiv Healthcare Company | $1,600.00 | 2019 | |
| Sanofi Pasteur INC. | $1,488.00 | 2021 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $825.12 | 2019-2024 | Jardiance, Spiriva Respimat, Ofev |
| Astrazeneca Pharmaceuticals LP | $465.72 | 2019-2025 | Fasenra |
| Mylan Specialty L.P. | $398.99 | 2019-2023 | Yupelri |
| Sunovion Pharmaceuticals INC. | $374.97 | 2019-2020 | |
| Actelion Pharmaceuticals US, INC. | $363.98 | 2019-2023 | Uptravi, Opsumit |
| Genentech USA, INC. | $306.92 | 2019-2022 | |
| Philips North America LLC | $288.52 | 2019-2021 | |
| Globus Medical, INC. | $255.82 | 2024 | Coalition |
| Electromed, INC. | $231.49 | 2019-2023 | Smartvest |
| Jazz Pharmaceuticals INC. | $220.65 | 2019-2025 | |
| Harmony Biosciences LLC | $207.12 | 2020-2025 |
Show all 37 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Genzyme Corporation | $184.77 | 2019-2025 | |
| Advanced Respiratory, INC | $182.46 | 2019-2020 | |
| Regeneron Healthcare Solutions, INC. | $174.87 | 2019-2023 | Dupixent |
| Grifols USA, LLC | $169.63 | 2020-2022 | |
| Merck Sharp & Dohme LLC | $168.95 | 2019-2025 | Belsomra |
| Eisai INC. | $165.20 | 2020-2021 | |
| Takeda Pharmaceuticals U.S.A., INC. | $127.56 | 2020-2025 | Glassia |
| Circassia INC. | $74.25 | 2019-2020 | |
| Gilead Sciences, INC. | $61.26 | 2019-2025 | |
| Shire North American Group INC | $44.83 | 2019 | |
| Amgen INC. | $37.90 | 2021-2022 | |
| Apria Healthcare LLC | $33.63 | 2021 | |
| Insmed, INC. | $25.23 | 2019-2020 | |
| Viatris Specialty LLC | $25.06 | 2025 | Yupelri |
| Verona Pharma, INC. | $24.99 | 2025 | Ohtuvayre |
| Idorsia Pharmaceuticals US INC | $24.93 | 2023 | Quviviq |
| Bayer Healthcare Pharmaceuticals INC. | $23.76 | 2021 | |
| Novartis Pharmaceuticals Corporation | $23.44 | 2020-2021 | |
| Abbvie INC. | $22.50 | 2021 | |
| Inspire Medical Systems, INC. | $21.57 | 2025 | Inspire |
| Teva Pharmaceuticals USA, INC. | $16.51 | 2022 | |
| Foundation Medicine, INC. | $13.66 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Lawrence Shulman listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.